• Aucun résultat trouvé

Active pharmaceutical ingredient (API)

A new combined LC (ESI+) MS/MS QTOF impurity fingerprinting and chemometrics approach for discriminating active pharmaceutical ingredient origins: example of simvastatin

A new combined LC (ESI+) MS/MS QTOF impurity fingerprinting and chemometrics approach for discriminating active pharmaceutical ingredient origins: example of simvastatin

... of active pharmaceutical ingredient (API) used in medicinal products is of highest interest for both the pharmaceutical industry and the regulatory ...

125

Dispersion of an Active Pharmaceutical Ingredient in Eudragit E100 by Melt Extrusion Coupled with Supercritical Carbon Dioxide

Dispersion of an Active Pharmaceutical Ingredient in Eudragit E100 by Melt Extrusion Coupled with Supercritical Carbon Dioxide

... dissolving active pharmaceutical ingredient, spironolactone was shown to reasonably improve the purity of the prepared solid dispersions by enabling production at lower temperature ...

9

Control of the dissolution rate of an active pharmaceutical ingredient by using melt extrusion coupled with supercritical CO2

Control of the dissolution rate of an active pharmaceutical ingredient by using melt extrusion coupled with supercritical CO2

... Control of the dissolution rate of an active pharmaceutical ingredient by using melt extrusion coupled with supercritical CO2.. 12th European Meeting on Supercritical Fluids, ISASF, May [r] ...

10

Comparative Study of Two Processes to Improve the Bioavailability of an Active Pharmaceutical Ingredient: Kneading and Supercritical Technology

Comparative Study of Two Processes to Improve the Bioavailability of an Active Pharmaceutical Ingredient: Kneading and Supercritical Technology

... in pharmaceutical formu- lations is the bioavailability of the active ...new Active Pharmaceutical Ingredients (API) are very poorly water ...low-solubility active molecules with ...

14

Use of supercritical CO2-aided and conventional melt extrusion for enhancing the dissolution rate of an active pharmaceutical ingredient

Use of supercritical CO2-aided and conventional melt extrusion for enhancing the dissolution rate of an active pharmaceutical ingredient

... RESULTS AND DISCUSSION Comparison of the melt and supercritical CO2‐aided extrusion techniques To improve the dissolution rate of CAR by forming solid dispersion or solution of the drug in the E100 matrix, both melt ...

11

COMPARATIVE STUDY OF ACTIVE PHARMACEUTICAL INGREDIENT QUANTITATION THROUGH THE PACKAGING USING HANDHELD SPECTROPHOTOMETERS BASED ON CONVENTIONAL AND SPATIALLY OFFSET RAMAN SCATTERING

COMPARATIVE STUDY OF ACTIVE PHARMACEUTICAL INGREDIENT QUANTITATION THROUGH THE PACKAGING USING HANDHELD SPECTROPHOTOMETERS BASED ON CONVENTIONAL AND SPATIALLY OFFSET RAMAN SCATTERING

... 2 Bio-Pharmaceutical and Toxicological Analysis Research Team, Laboratory of Pharmacology and Toxicology, Faculty of Medicine and Pharmacy, University Mohammed V, Rabat, Morocco Handheld Raman spectroscopy is ...

1

Influence of pH, Temperature and Impurities on the Solubility of an Active Pharmaceutical Ingredient (API)

Influence of pH, Temperature and Impurities on the Solubility of an Active Pharmaceutical Ingredient (API)

... Small amounts of solid (about 20 mg) were added each time and no addition was carried out before the solution was clear. When solubility was attained, solutions were kept un[r] ...

15

Does M&A create value in the pharmaceutical sector?

Does M&A create value in the pharmaceutical sector?

... changing pharmaceutical industry (heightened competition and consolidation trend), Sanofi-­‐Synthélabo decided to merge with Aventis as a defence ...the pharmaceutical industry, to ultimately benefit the ...

54

Application of EU Competition Law in the Pharmaceutical Sector

Application of EU Competition Law in the Pharmaceutical Sector

... the Pharmaceutical Sector Inquiry, which is somewhat ironic given that, in this Report, the Commission explicitly disavowed reaching any conclusions concerning the application of competi- tion law in the ...

14

Application of EU Competition Law in the Pharmaceutical Sector

Application of EU Competition Law in the Pharmaceutical Sector

... In assessing the FCA’s decision that such practices constituted an abuse, the Court of Appeal recalled that the language of Article 102 is broad, which means that a wide range of practices, including denigrating actual ...

12

Who cites non-English-language pharmaceutical articles?

Who cites non-English-language pharmaceutical articles?

... of pharmaceutical international journals; we selected journals on a practical considerations basis (availability in our University ...of pharmaceutical colleges in universities of some countries ...

7

Large scale flows in transitional plane Couette flow: a key ingredient of the spot growth mechanism Large scale flows in transitional plane Couette flow: a key ingredient of the spot growth mechanism

Large scale flows in transitional plane Couette flow: a key ingredient of the spot growth mechanism Large scale flows in transitional plane Couette flow: a key ingredient of the spot growth mechanism

... Large scale flows in transitional plane Couette flow: a key ingredient of the spot growth mechanism Large scale flows in transitional plane Couette flow: a key ingredient.. of the spot g[r] ...

11

Bayesian Design Space applied to Pharmaceutical Development

Bayesian Design Space applied to Pharmaceutical Development

... the pharmaceutical industry, the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), that regroups experts from the pharmaceutical ...

293

Continuous Plug Flow Crystallization of Pharmaceutical Compounds

Continuous Plug Flow Crystallization of Pharmaceutical Compounds

... The comparison of experimental and calculated values for crystal size distribution revealed that neither a plug flow model nor an axial dispersion model could describe accurately the continuous crystallization process, ...

34

Chitosan: a versatile platform for pharmaceutical applications

Chitosan: a versatile platform for pharmaceutical applications

... applications, PEGs with molecular weights of 2,000 to 10,000 Da are typically used to ensure renal clearance of degradation products. It is also possible to use bifunctional, α,ω-diami[r] ...

32

Demand and Supply Stability in the Pharmaceutical Industry

Demand and Supply Stability in the Pharmaceutical Industry

... Summary: A pharmaceutical company is facing instability in the planning process. Using analysis of real data, Root Cause Analysis, and interviews in the field, the thesis aims to investigate the main causes that ...

5

Pharmaceutical Applications of Molecular Tweezers, Clefts and Clips

Pharmaceutical Applications of Molecular Tweezers, Clefts and Clips

... the pharmaceutical applications of molecular tweezers, clefts and ...for Pharmaceutical Development of Molecular Tweezers? The past years have focused the efforts on optimizing the structure, to gain in ...

28

Active Knowledge

Active Knowledge

... When a particular fact about the scene is established, general knowledge of the hierarchical relevance of concepts should permit this fact to make relevant suggestions. The [r] ...

51

The Application of EU Competition Law in the Pharmaceutical Sector

The Application of EU Competition Law in the Pharmaceutical Sector

... prices’. Pharmaceutical companies will therefore need to take into account the possible competition law risk in deter- mining how aggressive a stance to take in pricing ...

14

Contextual Bandit for Active Learning: Active Thompson Sampling

Contextual Bandit for Active Learning: Active Thompson Sampling

... Multi-armed Bandit for Active Learning. To our knowledge there has been only two papers bridging the world of active learning and MAB. [7] adapted the EXP4 algorithm which is a MAB algorithm with expert ...

9

Show all 1633 documents...

Sujets connexes